Phase 2/3 trial results of Moderna’s COVID-19 vaccine in adolescents 12-17 years old show good safety, according to the company. The trial divided 3,732 participants into groups receiving the vaccine and placebo, with no COVID-19 cases documented among the group receiving the vaccine and 4 among the group receiving placebo. Some participants had side similar to adults including fatigue, headache and muscle pain. The company plans to seek authorization in early June to have approval for the vaccine expanded to the adolescent age group in the United States.